Introduction
============

Inflammatory bowel diseases (IBDs) comprise Crohn's disease and ulcerative colitis and are conditions presenting an overactive intestinal immune system. The exact etiology of these diseases is still unclear but may be related to genetic predisposition or environmental factors and is characterized by an inappropriate immune response taking to morpho-functional alterations of the host's enteric nervous system and intestinal secretory and motor dysfunctions. A loss of balance between the production of pro-inflammatory cytokines and anti-inflammatory mediators has been observed. Current therapeutic strategies are based on anti-inflammatory agents and targeted to achieve and maintain the remission state.

It is well established that during inflammation ATP is extracellularly released, a process involving pannexins or connexins and promoted by various stimuli ([@B38]; [@B52]). Extracellular ATP (eATP) is then degraded to adenosine by the ectonucleotidases CD39 and CD73 ([@B2]). While eATP generally plays a pro-inflammatory role through the activation of P2 (P2X and P2Y) purinergic receptors, the ATP degradation to adenosine usually represents a stop-signal for the inflammation process, with adenosine playing as anti-inflammatory agent through the activation of its P1 receptor targets. Adenosine is then removed from the extracellular environment by nucleoside transporters and/or metabolic enzymes.

Over the years increasing evidences pointed out a critical involvement of the purinergic system in the pathophysiology of IBDs, thus spurring the research toward the evaluation of the potential therapeutic benefits in terms of anti-inflammatory activity, arising by pharmacological targeting of purinergic pathways ([@B49]; [@B51]; [@B50]; [@B15], [@B16]; [@B19]). Furthermore, the involvement of ATP in the enteric motor dysfunctions associated with bowel inflammation is a hot topic deserving further investigations.

P2 Purinergic Receptors
=======================

P2X Purinergic Receptors
------------------------

P2X receptors are ligand-gated ion channels activated by eATP and permeable to Na^+^, K^+^, and Ca^2+^ ([@B77]; [@B76]). Seven P2X subtypes are known that may assemble as homo- or heterotrimers. Upon prolonged stimulation, some subtypes like the P2X7R undergo a rearrangement with the formation of a pore permeable to large molecules.

P2XR modulators are of great interest for several potential therapeutic applications, like treatment of pain, cough, cancer, and inflammation-related diseases ([@B20]; [@B91]; [@B72]). P2XR agonists are ATP derivatives obtained by modification of the purine base (i.e., 2-meSATP), the ribose ring (i.e., BzATP), or the polyphosphate chain (like the stable analogs αβ-meATP, βγ-meATP, and ATPγS) ([@B25]; [@B29]; [@B66]).

P2XR antagonists are generally negatively charged molecules like TNP-ATP ([@B94]) and analogs ([@B30]), the irreversible inhibitor oxidized ATP (o-ATP) ([@B73]), the P2X3R antagonist A-317491, and the polyanion suramin and its derivatives. Further classes of P2XR inhibitors are uncharged molecules based on heterocyclic scaffolds and behaving as non-competitive (allosteric) antagonists ([@B72]). A relevant number of structural classes of compounds were developed as P2X7R inhibitors ([@B82]) given the key role of this receptor in pain and inflammation-related conditions ([@B10]; [@B46]; [@B32]; [@B21]; [@B35]). P2X7R-targeting compounds have been developed also as radiolabeled molecules to be used as pharmacological tools or markers ([@B37]; [@B69]; [@B40]; [@B92]; [@B57]).

The potent, selective, and orally bioavailable P2X7R antagonist AZD9056 was studied in phase-two clinical trials for the treatment of rheumatoid arthritis (RA) and chronic obstructive pulmonary disease (COPD) showing to be well tolerated ([@B1]; [@B58]). The efficacy and safety of AZD9056 was also clinically assessed in the management of patients affected by moderate/severe Crohn's disease. Although the lack in change of inflammatory parameters, this study demonstrated that AZD9056 has the potential to improve symptoms, in particular abdominal pain, in patients with IBDs ([@B39]). Other P2X7R antagonists (CE-224,535 and GSK1482160) were studied in clinical trials for RA and inflammatory pain conditions or showed (JNJ47965567) ability to enter the CNS.

In a rat model of trinitrobenzene sulfonic acid (TNBS) colitis, the administration of the P2X7R inhibitor A740003 determined a reduction of T-cell and macrophage infiltration in the lamina propria, followed by a reduction in tissue TNF and IL-1β concentrations, with a consequent amelioration of inflammation severity ([@B71]). In parallel, [@B75] reported that mice lacking P2X7Rs and subjected to TNBS or dextran sulfate sodium (DSS) treatment failed to develop intestinal inflammation or other symptoms associated with colitis, thus indicating a protective role resulting from P2X7R blockade. In the same study, by exploring the expression of this receptor subtype in colonic mucosa of IBD patients, the authors observed high P2X7R levels in inflamed epithelium and lamina propria, where it colocalizes more with dendritic cells and macrophages, leading to hypothesize a role of P2X7R signaling in the pathogenesis of IBDs. Furthermore, [@B23] pointed out the pivotal role of P2X7R in the complex cross-talk occurring between intestinal epithelial cells and immune cells. The pharmacological stimulation of P2X7R in a human colonic epithelial cell monolayer induced caspase-1 activation and IL-1β release, pro-inflammatory mediators critically involved in the recruitment of polymorphonuclear leukocytes within the intestinal mucosa in the presence of inflammation. Subsequently, several preclinical studies performed in animal models of colitis revealed a significant role of P2X7R in the pathophysiology of intestinal inflammation ([@B71]; [@B75]; [@B97]). Increasing efforts have been made to investigate the involvement of purinergic pathways in the pathophysiology of enteric motor dysfunction typically observed in the presence of intestinal inflammation, although the available data are fragmentary ([@B4]). Recently, [@B9] provided evidence about a marked increase in P2X7R immunostaining, and an enhanced modulating action of these receptors on colonic neuromotility in a rat model of DNBS-induced colitis.

Beside the importance of the P2X7R in the gastrointestinal diseases described in literature, recent papers suggest that even other P2X subtypes could play a relevant role the gastrointestinal pathophysiology ([@B83]; [@B98]; [@B47]). Antagonists of the P2X3R showed promising activity in alleviating inflammatory and neuropathic pain in preclinical studies. A-317491 reduced visceral hypersensitivity in an experimental model of colitis, suggesting P2X3R as target for the treatment of inflammation-related abdominal pain syndromes ([@B34]).

P2Y Purinergic Receptors
------------------------

P2Y receptors are G protein-coupled receptors of which eight subtypes (P2Y~1~, P2Y~2~, P2Y~4~, P2Y~6~, and P2Y~11-14~) are currently known. The endogenous agonists of these receptors are ATP, ADP, UTP, UDP, and UDP-glucose, with each P2Y subtype presenting peculiar pharmacological properties and preference for di- or triphosphate nucleotides ([@B56]). P2YRs are widely expressed in the body and involved in several biological functions. Beside the well-known inhibition of platelet aggregation, for which P2Y~12~R modulators like Clopidogrel, Prasugrel, Cangrelor, and Ticagrelor are approved for human use, P2YRs play important roles in neurotransmission and modulation of immune system ([@B67]).

P2YR ligands were developed by modification of endogenous ligands at the base (i.e., 2-thioUTP or 2-MeSATP), the sugar (i.e., MRS2365), or the phosphate chain (i.e., PSB1114) ([@B96]; [@B53]; [@B26]; [@B56]). Dinucleoside derivatives are also ligands of the P2YRs. Diquafosol (approved in Japan for the treatment of Dry Eye disorder) and Denufosol (clinically evaluated for bronchial indication in cystic fibrosis) are representative compounds of this category and are endowed with dual P2Y~2~/P2Y~4~ receptor agonist profile. Suramin-based compounds are also P2YR modulators. Yet, several P2YR ligands belong to other structural classes not necessarily containing negatively charged functions ([@B26]).

Considering the role of the P2Y~2~, P2Y~6~, and P2Y~12~ receptors in the inflammation-related conditions, compounds acting on these P2Y subtypes have been evaluated in such frames. P2Y~12~R antagonists present interesting potential to prevent a chronic inflammation promoted by this protein and to modulate the inflammatory pain ([@B93]; [@B11]). Focusing on the bowel-related conditions, [@B44], investigating the role of ATP receptors in the pathogenesis of intestinal inflammation, reported that the pro-inflammatory cytokines TNF-α or IFN-γ determined an increased expression of P2Y~2~ and P2Y~6~ receptors in the colonic mucosa of mice with DSS colitis ([@B44]; [@B33]). Noteworthy, the pharmacological activation of P2Y~2~R via 2-thioUTP in a mouse model of DSS-induced colitis reduced the disease activity index and histological score values as well as a decrease in bacterial translocation to the spleen when compared with untreated mice, thus highlighting a protective role of P2Y~2~R in sustaining the remission phase in this experimental model of colitis ([@B33]). By contrast, stimulation of the P2Y~6~R led to the activation of calcium-independent PKCδ upstream of ERK1/2, followed by the stimulation of c-fos phosphorylation and the recruitment of c-fos/c-jun dimers at level of the AP-1 motif located within the core promoter region of IL-8 gene, thus determining an increase of IL-8 release ([@B45]). Despite these encouraging results, further investigations are needed to evaluate the putative beneficial effect of P2Y~2~ and P2Y~6~ receptor ligands in counteracting intestinal inflammation.

Considering the enteric motor dysfunction associated to intestinal inflammation, interesting findings were provided about the involvement of P2Y~1~R in the regulation of colonic neuromuscular activity in a model of TNBS-induced colitis in guinea-pig ([@B90]). Inflamed colonic specimens displayed a marked decrease in the fecal pellet output and a significant reduction of inhibitory junction potential (IJP). Of note, the pharmacological analysis of the determinant of IJP revealed that the purinergic component, mediated by P2Y~1~R, was impaired, despite immunohistochemical assays did not display significant alterations of nerve fiber density in circular muscle strips from animals with colitis ([@B90]).

P1 Adenosine Receptors
======================

Adenosine Receptors (P1 receptors or ARs) are G protein-coupled receptors known as four subtypes (A~1~AR, A~2A~AR, A~2B~AR, and A~3~AR). Like the other Purinergic Receptors, ARs are widely expressed in the body and regulate many physiological functions. The endogenous ligand adenosine has a short half-life as it is internalized by nucleoside transporters and/or quickly modified to inosine by Adenosine Deaminase (ADA) or to AMP by Adenosine Kinase (ADK).

Medicinal chemistry efforts were aimed at developing compounds presenting higher metabolic stability and improved potency and selectivity compared to the endogenous ligand ([@B28]; [@B54]; [@B99]; [@B24]). A key modification of adenosine is the introduction of a *N*-alkyl-carboxamido function in the 4′-position to obtain NECA (*N*-ethyl) or MECA (*N*-methyl) derivatives, with an improved potency at all the ARs. Typical A~1~AR and A~3~AR agonists contain bulky groups in the *N*^6^-position combined with modifications in the 2-position ([@B60]; [@B59]; [@B95]). Reference A~3~AR agonists are IB-MECA and Cl-IB-MECA, in clinical trials for inflammation-related conditions (RA and psoriasis) ([@B13]; [@B55]). A~2A~AR agonists are generally NECA derivatives presenting complex chains in the 2-position (i.e., CGS21680, ATL-146e, and ATL-313 where the 4′-carboxamido group is further modified). High A~2A~AR affinity and selectivity was obtained by inserting a bulky arylalkyl function in the *N*^6^-position to obtain UK-432097 ([@B31]).

About the molecules able to block the AR function, AR antagonists are generally divided in non-xanthine- and xanthine-based derivatives. Non-xanthine AR antagonists are based on a large variety of scaffolds (generally heterocycles). Reference compounds for pharmacological studies at ARs may be found within this heterogeneous group, some of which were developed also as water-soluble molecules, pro-drugs, and radiolabeled compounds. Xanthine-based AR antagonists contain the A~2A~AR inhibitor Istradefylline that was approved to market in Japan as antiparkinsonian tool ([@B56]).

At present, most of available studies investigating the role of AR signaling in several experimental models of colitis showed remarkable beneficial effects upon pharmacological modulation of A~2A~AR ([@B78]; [@B22]; [@B74]; [@B84]; [@B7]; [@B81]). The A~2A~AR agonists ATL-146e or ATL-313 significantly reduced mucosal inflammation of colon, with a marked decrease in pro-inflammatory cytokine levels and in leukocyte infiltration and an increase of levels of anti-inflammatory cytokines ([@B74]; [@B79]). Recently [@B81] demonstrated the beneficial effects arising from A~2A~AR stimulation with polydeoxyribonucleotide in two experimental models of colitis. In the DSS model polydeoxyribonucleotide could counteract the hemorrhagic diarrhea, improve the weight loss, and restore the anatomic integrity of damaged epithelial and mucosal layers. In the DNBS model, polydeoxyribonucleotide markedly reduced the inflammatory response as well as the granulocytic infiltration into the mucosal and submucosal layers and, therefore, decreased the pro-inflammatory cytokines TNF and IL-1β, MPO activity and lipid peroxidation in colon samples. Noteworthy, polydeoxyribonucleotide treatment also affected Bax and Bcl-2 expression, reducing apoptotic and necrotic cells in all tissue layers. By contrast, no beneficial effects have been reported upon administration of CGS21680 in mouse model of DSS-induced colitis ([@B88]). Further investigations are needed to better characterize the therapeutic potential of A~2A~AR agonists in IBDs. A number of evidences reported that aging is often associated with a chronic, low-grade systemic inflammatory condition ([@B65]), that could predispose to the gastrointestinal alterations typical of the elderly subject ([@B85]). Recently, it has been demonstrated that the reduction of A~2A~AR in the digestive tract of aged mice, contributes to an increased inflammation and lower ability to counteract gut infection with deleterious effects in the elderly ([@B87]).

Another promising option aimed at counteracting the bowel inflammation is the pharmacological stimulation of A~3~AR ([@B43]; [@B5]). The administration of IB-MECA revealed to afford a protective role in murine models of intestinal inflammation ([@B70]; [@B48]). In detail, the pharmacological engagement of A~3~AR determined the inhibition of several cytokine/chemokine/inflammatory genes, thus promoting a marked down-regulation of several pro-inflammatory mediators (MIP-1α and MIP-2, IL-1, IL-6, IL-12) and the production of reactive species of oxygen, determining an improvement of the intestinal damage ([@B48]). A recent preclinical study by [@B86] showed that the pharmacological stimulation of A~3~AR with Cl-IB-MECA inhibited the NF-κB pathway in the colonic epithelia of DSS colitis mice. The inhibition of both NF-κB activation and IκBa phosphorylation caused a reduction of pro-inflammatory cytokines expression in colonic epithelia of inflamed animals.

Finally, the evidence supporting an over-expression of A~2B~AR in experimental colitis has sparked interest on the potential therapeutic implications of these intriguing receptor subtype ([@B61]). The same research group ([@B62]; [@B63]) demonstrated also a critical role of intestinal epithelial A~2B~AR in the pro-inflammatory activity exerted by adenosine in animals with TNBS or DSS colitis. The treatment with the A~2B~AR antagonist ATL-801 to mice with experimental colitis ameliorated several inflammatory parameters, leading to a beneficial impact on the disease progression ([@B62]). By contrast, [@B42] reported a detrimental effect exerted by the A~2B~AR inhibitor PSB1115 in the acute phase of DSS-induced colitis, thus questioning the beneficial effect of A~2B~AR blockade in the management of IBDs.

Regulation of Extracellular Adenosine Levels
============================================

Several authors investigated the efficacy of pharmacological treatments aimed at increasing the levels of endogenous adenosine, through the blockade of pivotal catabolic enzymes, as an alternative way to counteract intestinal inflammation. eATP is rapidly degraded to adenosine by ectonucleotidases CD73 and CD39. Genetic deletion of these enzymes prompts a higher susceptibility to inflammatory states or more severe progression of inflammation in IBD experimental models ([@B52]; [@B68]). Polymorphisms taking to lower ectonucleotidases expression takes to analog scenarios ([@B52]). By contrast, blockade of nucleoside transporters leads to an increase of extracellular adenosine levels, with a consequent improvement of the inflammation course in IBD models ([@B100]). The extracellular levels of adenosine are also regulated by the activity of metabolic enzymes like ADK and ADA ([@B27]). The blockade of these enzymes is associated to anti-inflammatory effects and was preclinically tested as strategy to ameliorate intestinal inflammation-related conditions. [@B89] reported, for the first time, an anti-inflammatory effect of the ADK inhibitor GP515 in a mouse model of colitis. Encouraging ameliorative effects were observed also following the inhibition of ADA in murine models of intestinal inflammation ([@B8], [@B6], [@B3]; [@B64]), with reduction of the colonic inflammatory damage and decrease in tissue levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IFN-γ, and chemokine C-X-C motif ligand 10), as well as a reduction of neutrophil infiltration and ROS production ([@B8], [@B6]; [@B14]; [@B64]). Noteworthy, it was observed that the attenuation of colonic injury, following ADA blockade, was mediated mainly by the engagement of A~2A~AR and, to a lesser extent, A~3~AR ([@B6]).

Conclusion
==========

Several pre-clinical studies pointed out a key role for the purinergic system in the modulation of inflammatory and immune responses. Furthermore, clinical evaluation of purinergic ligands for the treatment of inflammation-related conditions (i.e., RA and psoriasis but also IBDs for a P2X7R inhibitor) showed a good tolerability of these molecules and suggests further investigations for this strategy. **Figure [1](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}** provide a schematic overview of the purinergic signal contributions in the intestinal tract and the most promising purine-based therapeutic strategies for the intestinal disorders.

![Schematic figure with the putative contribution of the main purinergic signals (ATP and adenosine) and their different receptors (P2X3, P2X7, P2Y~1,2,6~, A~2A~, and A~3~) in different cell types of the intestinal tract.](fphar-09-00212-g001){#F1}
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Promising pharmacological tools acting on purinergic receptors to manage intestinal disorders.

  Intestinal Diseases                  Pharmacological Target
  ------------------------------------ --------------------------------------------
  Inflammatory bowel diseases (IBDs)   P2X7R antagonists
                                       A~2A~AR agonists
                                       A~2B~AR antagonists
                                       A~3~AR agonists
  Irritable bowel syndrome (IBS)       P2X3R antagonists
                                       P2X7R antagonists
                                       A~3~AR agonists (?)
  Functional motor disorders           A~1~AR antagonists (post-operative ileus)
                                       A~2A~AR antagonists (functional dyspepsia)
                                       A~2B~AR antagonists (constipation)
                                       A~3~AR antagonists (constipation)
  Visceral pain                        P2X3R antagonists
                                       P2X7R antagonists
                                       A~1~AR agonists (?)
                                       A~2A~AR agonists (?)
                                       A~3~AR agonists (?)
  Diarrhea                             P2X3R antagonists
                                       P2Y~1~R antagonists (?)
                                       P2Y~2~R antagonists (?)
                                       P2Y~6~R antagonists (?)
                                       A~2A~AR agonists
                                       A~2B~AR antagonists
                                       A~3~AR agonists (?)

The (?) symbols indicate that the therapeutic potential arises from some literature contributions but is not yet clearly confirmed

.

Despite clinical studies demonstrated an encouraging profile in terms of tolerability for AZD9056, a novel P2X7R antagonist, it displayed a limited efficacy in the management of patients affected by moderate/severe Crohn's disease. In parallel, an increasing interest has been payed toward the A~2A~AR (and the A~3~AR) agonists as viable way to manage digestive dysfunctions. However, despite promising the available evidences are limited to the pre-clinical phase and deserve further translational and clinical insights before highlighting their therapeutic potential. In this context, Michael Sitkovsky ([@B41]; [@B80]) undoubtedly provided several of the most eminent scientific evidences about the therapeutic potential of ligands acting on this receptor subtype, paving the way toward their next clinical employment.

Apart from animal studies, the unique window of opportunity to grasp the relevance of part of the purinergic system, operated by adenosine receptors, in intestine function, is offered by the consumption of caffeine, which only known target at non-toxic conditions is the antagonism of adenosine receptors. In this regard, there are evidences, despite conflicting, about the association between caffeine consumption and the onset and development of gastrointestinal-related disorders. In particular, several authors reported a direct association between coffee consumption and some functional digestive disorders (i.e., gastro-oesophageal reflux, dyspepsia, irritable bowel syndrome) ([@B12]; [@B36]).

These data boost the medicinal chemistry toward the synthesis of novel pharmacological entities acting selectively on specific purinergic receptors/enzymes and endowed with improved pharmacodynamic and pharmacokinetic profiles. These molecules would definitively help to clearly depict the pathophysiological role and the therapeutic potential of these proteins and would represent a key step for the development of useful tools for the management of intestinal inflammatory disorders ([@B17],[@B18]; [@B19]).
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